Arena Pharmaceuticals reviews lower net lack of $31.

This decrease is primarily attributable to the completion of our pivotal Stage 3 scientific trials for lorcaserin. Analysis and development expenses included $0.9 million in non-cash, share-based compensation expense in both of the quarters ended March 31, 2010 and 2009. General and administrative expenses totaled $7.0 million in the first quarter of 2010, in comparison to $7.6 million in the first quarter of 2009. This reduction in general and administrative expenses is attributable to reduced corporate and patent legal fees primarily.This full year 401 members have already been awarded this honor by AAAS. On Saturday New Fellows will be offered the official certificate and a rosette pin, 14 February, 2015, at the AAAS Fellows Forum through the 2015 AAAS Annual Interacting with in San Jose, CA.

Certain SSRI medications fail to achieve same selectivity for prevention of SUDEP Scientists from Southern Illinois University today reported the results of a study evaluating the potential aftereffect of two selective serotonin reuptake inhibitors antidepressant medications in reducing the chance of sudden unexpected death in epilepsy . In a written report offered at the American Epilepsy Society's 66th Annual Meeting, the study team discovered that certain SSRI medications in the study didn’t achieve the equal selectivity for avoidance of SUDEP while fluoxetine, an SSRI they had investigated previously.